ClinicalTrials.gg
CompletedNCT05585398Updated Jun 22, 2023

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

A Phase 1 interventional study of IncobotulinumtoxinA in N/A, as no Specific Medical Condition Will be Treated, sponsored by Merz Pharmaceuticals GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Merz Pharmaceuticals GmbH (part of Merz Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different delivery methods (conventional needle and microneedles).

02

Conditions studied

  • N/A, as no Specific Medical Condition Will be Treated
03

In context

Lead sponsor

Merz Pharmaceuticals GmbH is the lead sponsor of 61 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subject aged 18 to 45 years with (BMI) 19.0 to 27.0 kg/m².
  • Subject with the distance not less than 45 cm between the spinous process of the 7th cervical vertebra (C7) and the 4th lumbar vertebra (L4).
  • Healthy skin at test area (forehead and back).
  • Fitzpatrick skin type I to IV.
  • Displaying uniform sweating activity (i.e., symmetrical sweating pattern with enough sweat and without anhidrotic regions) on the forehead area as assessed with Minor's starch iodine test under standardized sweating conditions.

Exclusion criteria

Exclusion Criteria:

  • Any chronic pain conditions or presence of acute pain of any origin and intensity.
  • Dermal treatment of the forehead (e.g., light resurfacing, dermabrasions) within the last 12 months before Screening, during the screening period, and/or at Baseline.
  • Any type of filler in the treatment area on the facial region within the last 12 months before Screening, during the screening period, and/or atBaseline; regardless of time for any type of implant and/or surgery in the treatment area on facial region.
  • Any type of surgery in the treatment area of the back within the last 12 months before Screening, during the screening period, and/or at Baseline.
  • Treatment with anticholinergics within the last 14 days before Screening, during the screening period, and/or at Baseline.
  • Treatment with analgesics (e.g., non steroidal anti inflammatory drugs, except acetylsalicylic acid, ibuprofen, and paracetamol) within the last 10 days before Screening, during the screening period, and/or prior to pain assessment at Baseline.
  • Treatment with paracetamol, ibuprofen, or acetylsalicylic acid within three days prior to pain assessment at Baseline.
  • Subjects with excessive sweating or previously diagnosed with hyperhidrosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    LMRC (left with micro-/right with conv- needle)

    Drug: IncobotulinumtoxinA

  • Experimental
    RMLC (right with micro-/left with conv- needle)

    Drug: IncobotulinumtoxinA

  • Experimental
    LCRM (left with conv-/ right with micro-needles)

    Drug: IncobotulinumtoxinA

  • Experimental
    RCLM (right with conv-/left with micro-needles)

    Drug: IncobotulinumtoxinA

Interventions

  • Intradermal injections using different delivery methods (conventional needle and microneedles)

    Also known as: Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins

06

What researchers measure

Primary outcomes

  1. Area of anhidrosis on contralateral points of the forehead four weeks after intradermal injections of NT 201 with fixed dose and volume, using different delivery methods

    Time frame: Week 4

Secondary outcomes

  1. Injection pain intensity as assessed by a 0-10 numeric pain rating scale directly after the intradermal injection of NT 201 applied via different delivery methods in the forehead

    Time frame: Week 4

07

Study locations

1 site
  • Merz Investigational Site #0490385
    Hamburg, 20095, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Feb 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 18, 2022
StartActual
Oct 19, 2022
Primary completionActual
Feb 24, 2023
CompletionActual
Apr 13, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05585398
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Oct 19, 2022
Primary completion
Feb 24, 2023
Completion
Apr 13, 2023
Last update
Jun 22, 2023

Study contacts

Merz Medical Expert
study director · Merz Therapeutics GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion